AYVAKIT® Approved for Treatment of Indolent Systemic Mastocytosis


The Mast Cell Disease Society is very excited to share the news of the FDA approval of AYVAKIT®(avapritinib).

This is the first and only FDA approved treatment for Indolent Systemic Mastocytosis!

To learn more, check out Blueprint Medicine’s press release and patient community letter!
Skip to content